Insmed Incorporated
INSM
Clasificación en acciones
#1105
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Precio por acción
$96.65
Última sincronización: 2026-10-16
Capitalización bursátil
$21.11B
Cambio (1 día)
-2.59%
Cambio (1 año)
-41.70%
País
US
Comercio Insmed Incorporated (INSM)
Categoría
Healthcare
Margen Operativo de Insmed Incorporated (INSM)
Margen Operativo al October 2026 TTM: -71.86%
Según los informes financieros más recientes y el precio de las acciones de Insmed Incorporated, el margen operativo actual (TTM) es -71.86%. Al final de 2023, el margen operativo era -232.51%.
Historial de Margen Operativo de Insmed Incorporated desde 2000 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | -71.86% | -70.24% |
| 2024 | -241.47% | 3.85% |
| 2023 | -232.51% | 19.32% |
| 2022 | -194.87% | -0.14% |
| 2021 | -195.14% | 20.96% |
| 2020 | -161.32% | -6.42% |
| 2019 | -172.38% | -94.48% |
| 2018 | -3,124.94% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -759.70% | 58.80% |
| 2013 | -478.39% | 0.00% |
| 2012 | 0.00% | -100.00% |
| 2011 | -1,397.31% | 1,095.10% |
| 2010 | -116.92% | 39.82% |
| 2009 | -83.62% | -32.12% |
| 2008 | -123.18% | -54.62% |
| 2007 | -271.47% | -95.05% |
| 2006 | -5,486.68% | -73.80% |
| 2005 | -20,941.98% | 4.61% |
| 2004 | -20,018.25% | 183.65% |
| 2003 | -7,057.33% | 272.65% |
| 2002 | -1,893.81% | -86.05% |
| 2001 | -13,576.35% | -90.01% |
| 2000 | -135,891.67% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -100.54% |
US
|
|
| -149.01% | -97.93% |
US
|
|
| 25.57% | -100.36% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.40% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.